PUBLISHER: The Business Research Company | PRODUCT CODE: 1751028
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751028
Intravenous (IV) Ibuprofen is a medication administered directly into the bloodstream through an intravenous route, primarily used for providing rapid pain relief and reducing inflammation or fever, especially in patients who are unable to take oral medications. It works by inhibiting the production of prostaglandins, which are responsible for causing pain and inflammation. IV ibuprofen is commonly used in clinical settings, particularly for postoperative pain and other acute conditions that require quick relief.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main product types in the intravenous (IV) ibuprofen market include conventional intravenous (IV) ibuprofen and high-concentration intravenous (IV) ibuprofen. Conventional intravenous (IV) ibuprofen is the standard formulation used to administer ibuprofen directly into the bloodstream for pain relief, inflammation reduction, and fever management, typically in hospital settings for acute or postoperative pain. The available strengths for intravenous ibuprofen include 100 mg, 200 mg, 400 mg, and 800 mg. IV ibuprofen is used for a range of conditions, including pain, fever, and inflammation, across different age groups, including pediatrics and adults. The key end-users include hospitals, ambulatory surgical centers, clinics, and other healthcare settings.
The intravenous (IV) ibuprofen market research report is one of a series of new reports from The Business Research Company that provides intravenous (IV) ibuprofen market statistics, including intravenous (IV) ibuprofen industry global market size, regional shares, competitors with a intravenous (IV) ibuprofen market share, detailed intravenous (IV) ibuprofen market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous (IV) ibuprofen industry. This intravenous (IV) ibuprofen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The intravenous (IV) ibuprofen market size has grown rapidly in recent years. It will grow from$8.35 billion in 2024 to $9.4 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to several factors, including the increasing prevalence of chronic diseases, a rise in surgical procedures, and a growing emphasis on minimizing opioid usage.
The intravenous (IV) ibuprofen market size is expected to see rapid growth in the next few years. It will grow to$14.86 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth during the forecast period can be attributed to several factors, including higher healthcare investments, a growing pediatric patient population, an increase in the prevalence of pain and fever, an aging population, and a rise in the adoption of advanced pharmaceutical treatments. Key trends during this period include the development of advanced therapeutic solutions, the emergence of single-dose formulations, progress in personalized medicine, integration into multimodal pain management protocols, and advancements in combination therapies.
The growing prevalence of pain disorders is expected to drive the growth of the intravenous ibuprofen market in the coming years. Pain disorders are medical conditions characterized by persistent or chronic pain that impairs daily functioning, often due to nerve, musculoskeletal, or inflammatory issues. The increase in pain disorders is largely attributed to the aging population, as older adults are more likely to develop chronic conditions such as arthritis, osteoarthritis, and nerve pain, leading to a higher demand for effective pain relief. Intravenous ibuprofen aids pain management by providing rapid relief, making it particularly suitable for acute and postoperative pain. It works by reducing inflammation and enhancing patient comfort, improving the overall effectiveness of treatment in medical settings. For example, in January 2024, the Office for Health Improvement and Disparities in the UK reported that the percentage of individuals aged 16 and older who self-reported having a long-term musculoskeletal condition increased to 18.4% in 2023, up from 17.6% in 2022. As a result, the rising prevalence of pain disorders is contributing to the growth of the intravenous ibuprofen market.
Companies in the intravenous ibuprofen market are focusing on developing advanced drug formulations, such as opioid-free analgesics, to improve pain management while reducing the risk of opioid dependence. An opioid-free analgesic is a pain-relieving medication that does not contain opioids, thereby eliminating the risks of addiction and opioid-related side effects. For instance, in February 2024, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced COMBOGESIC IV (acetaminophen and ibuprofen) injection in the U.S. following FDA approval in October 2023. This intravenous, opioid-free analgesic is intended for the relief of mild to moderate pain and as an adjunct for managing moderate to severe pain. By combining two active ingredients with distinct mechanisms of action, COMBOGESIC IV offers a novel non-opioid pain management solution for healthcare providers.
In May 2024, Halex Istar Industria Farmaceutica SA, a Brazil-based pharmaceutical company, entered into a partnership with AFT Pharmaceuticals Ltd. to expand the distribution of Maxigesic IV (paracetamol + ibuprofen IV) in Brazil. This collaboration aims to provide effective non-opioid pain management solutions to the Brazilian market. AFT Pharmaceuticals Ltd., based in New Zealand, specializes in intravenous pain relief products.
Major players in the intravenous (iv) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Grifols S.A., Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, CSL Limited, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Recordati Rare Diseases Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, and Hyloris Pharmaceuticals SA.
North America was the largest region in the intravenous (IV) ibuprofen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intravenous (IV) ibuprofen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the intravenous (IV) ibuprofen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The intravenous (IV) ibuprofen market consists of sales of pediatric intravenous (IV) ibuprofen, intravenous (IV) ibuprofen concentrate and pre-mixed intravenous (IV) ibuprofen bags. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Intravenous (IV) Ibuprofen Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on intravenous (iv) ibuprofen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for intravenous (iv) ibuprofen ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intravenous (iv) ibuprofen market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.